SHRED Blend – The Cutting Stack

SHRED is the growth-hormone route to fat loss, with four compounds pulling in the same direction. AOD-9604, CJC-1295, Ipamorelin and MOTS-c in one pre-mixed vial — the GH-axis counterpart to FUSION, aimed at body composition rather than appetite. 🔥 SHRED Blend — The Cutting Stack Four compounds, one direction. What it is, in plain English Growth hormone falls with age, and it is the hormone most associated with how the body partitions fuel — whether a calorie is stored or burned. SHRED works that axis from three angles at once. CJC-1295 and Ipamorelin prompt the pituitary to release its own growth hormone in a natural pulse. AOD-9604 is a fragment of the growth-hormone molecule isolated for its effect on fat metabolism, without the blood-sugar effects of the whole hormone. MOTS-c comes at it from inside the mitochondria instead, where fuel is actually burned. How it helps 🔥 Four compounds aimed at body composition, not appetite 🌙 CJC-1295 and Ipamorelin work with the overnight GH pulse ⚡ MOTS-c targets mitochondrial fuel use directly 💧 Arrives pre-mixed — nothing to reconstitute Why people reach for it People who have already worked the appetite lever — a GLP-1, or tesofensine — often find the scale moves but body composition does not. SHRED is aimed at that second problem. It is also the reason it sits alongside a GLP-1 in practice rather than replacing one. FUSION Blend SHRED Blend Approach Metabolic and tissue repair Growth-hormone axis Contains BPC-157, MOTS-c, 5-Amino-1MQ, Tesamorelin AOD-9604, CJC-1295, Ipamorelin, MOTS-c Shared compound MOTS-c MOTS-c Is it a fit? SHRED suits someone focused on body composition who is comfortable with a growth-hormone-axis protocol. Anyone whose main obstacle is appetite should look at the GLP-1 range or FUSION first. Take the 60-second peptide quiz or message our team, and our providers can point the way. 🔬 For the science-minded AOD-9604 is a modified fragment of human growth hormone (residues 176-191) studied for lipolytic activity without the insulin-antagonising effects of the full molecule. CJC-1295 is a growth-hormone-releasing hormone analogue and Ipamorelin a selective growth-hormone secretagogue receptor agonist; together they raise pulsatile growth-hormone release and IGF-1. MOTS-c is a mitochondrial-derived peptide reported to activate AMPK and improve metabolic flexibility. Human trial data vary considerably across the four. This is a growth-hormone-axis protocol. It can raise blood sugar and reduce insulin sensitivity, and it is not appropriate for anyone with a personal history of cancer. Anyone with diabetes or prediabetes should discuss it with a provider before starting. Educational only — not medical advice. Peptides discussed here are research compounds; whether any is appropriate is a decision between a patient and their licensed provider.